CN114660197A - A detection method for the determination of liquid crystal monomer compounds in mammalian organs - Google Patents

Abstract

The invention discloses a detection method for determining liquid crystal monomer compounds in mammalian organs, and belongs to the technical field of pollutant monitoring and control. The method includes pre-processing mammalian organs, and extracting samples containing liquid crystal monomers in the organs; using GC-MS to detect the obtained sample samples to obtain the content of liquid crystal monomers. It can accurately measure liquid crystal monomer compounds in mammalian organs.

Description

A detection method for the determination of liquid crystal monomer compounds in mammalian organs

technical field

The invention relates to the technical field of pollutant monitoring and control, and more particularly, to a detection method for measuring liquid crystal monomer compounds in mammalian organs.

Background technique

Liquid Crystal Monomers (LCMs) are an important class of organic compounds composing liquid crystal displays. As a large number of liquid crystal displays go through the life cycle of production, use, and end-of-life, LCMs are frequently detected in the environment as an emerging organic pollutant. Recent studies have shown that LCMs have environmental persistence and toxicity similar to dioxins and PCBs, and their potential health risks deserve close attention. The four target liquid crystal monomer compounds concerned by the present invention are: propyl-3,4-difluorobiphenyl (3dFB), 4-ethoxy-2,3-difluoro-4'-propyl-1,1 '-biphenyl (2OdF3B), ethylphenyl-2',3,4,5-tetrafluorobiphenyl (2teFT) and hexyloxybiphenylnitrile (6OCB). Among them, 3dFB, 2OdF3B and 2teFT are fluorine-containing liquid crystal monomers, and they are also the types that exist in the current reported environment and have greater potential harm; 6OCB is a liquid crystal monomer containing cyano groups, and cyano liquid crystal monomers are also an important part. , with potential environmental hazards.

At present, there is no extraction, purification and detection method for LCMs in mammalian organs and tissues, and there are few researches and applications on the extraction and detection methods of LCMs in environmental media. At present, some reports mainly use accelerated solvent extraction, ultrasonic-assisted liquid-liquid extraction, and self-filling purification columns to extract and detect LCMs from dust and sediment in the environment. The above method has disadvantages such as large amount of solvent used, cumbersome operation, and difficulty in popularization and implementation. Therefore, establishing a fast, accurate, robust, low-cost, and safe detection method has become an urgent requirement for the determination of LCMs in mammalian organs, and also provides a convenient method reference for the detection of LCMs in environmental monitoring and human health monitoring in the future.

SUMMARY OF THE INVENTION

1. The problem to be solved

Based on the current lack of extraction and detection methods for LCMs in mammalian organs and tissues, the present invention provides a detection method for rapid determination of liquid crystal monomer compounds in mouse organs.

2. Technical solutions

In order to solve the above problems, the technical scheme adopted in the present invention is as follows:

A detection method for determining liquid crystal monomer compounds in mammalian organs, comprising the following steps:

1. Pre-processing mammalian organs, and extracting samples containing liquid crystal monomers in the organs;

2. Use gas chromatography-tandem mass spectrometry (GC-MS) to detect the obtained sample sample to obtain the content of the liquid crystal monomer;

Wherein, the preprocessing includes the following operations:

S1. freeze-drying the organ;

S2. Grinding after freeze-drying;

S3. Extracting the ground organ powder with an acetonitrile solution containing formic acid; then taking the supernatant for drying and redissolving to obtain the sample containing the liquid crystal monomer.

Further, the supernatant includes a primary supernatant, and the primary supernatant is obtained in the following manner: vortexing, ultrasonic/oscillation, vortexing, and centrifugation;

Further, in the process of obtaining a supernatant, the first vortex time is 5-15min, the ultrasonic/oscillation time is 10-30min, the second vortex time is 5-10min; the centrifugation time is 5-15min, and the centrifugal speed is 5-15min. It is 3000～5000rpm.

Further, the pretreatment also includes a step of removing impurities from the supernatant, specifically: taking a supernatant to bond silica gel with octadecylsilane (hereinafter referred to as C18) and/or ethylenediamine-N-propane Silane (hereinafter referred to as PSA) and/or graphene (hereinafter referred to as GCB) are used as impurity removers, and the primary supernatant after the removal of impurities is vortexed and centrifuged to obtain the secondary supernatant, and then the secondary supernatant is treated. The liquid is dried and reconstituted to obtain the sample sample containing the liquid crystal monomer.

Further, the usage amount of the octadecylsilane-bonded silica gel (C18) needs to be 70-100mg/0.1g organ powder;

The usage amount of the ethylenediamine-N-propylsilane (PSA) needs to be 90-110 mg/0.1 g organ powder.

Further, in the process of obtaining the secondary supernatant, the vortexing time is 10-60s, preferably 10-30s, the centrifugation time is 5-30min, preferably 5-30min, and the centrifugal speed is 3000-5000rpm, Preferably it is 4000-5000rpm.

Further, the drying method is air-blown drying; preferably, the secondary supernatant liquid is subjected to air-blowing treatment to dryness by using nitrogen gas.

Further, the formic acid-containing acetonitrile solution is a 0-0.2% formic acid (v/v) acetonitrile solution.

Further, the GC-MS detection conditions are as follows:

Gas chromatography conditions: Column: HP-5MS capillary column (30m×0.25mm×0.25μm); carrier gas: high-purity helium, purity ≥99.999%, flow rate 1.0mL min-1; injection method: splitless injection Injection volume: 1 μL; Injector temperature: 290°C; Temperature program: 100°C at 25°C/min to 250°C, hold for 3min, then 10°C/min to 270°C, hold for 1min, then Rise to 280°C at 10°C/min and hold for 4 min.

Mass spectrometry conditions: ion source temperature: 280°C; transfer line temperature: 290°C; solvent delay: 5 min; acquisition mode: SIM scan. The detection parameters of the four LCMs used in this study are shown in Table 1:

Table 1 Detection parameters of the four LCMs used in this study

Further, use GC-MS to detect and extract samples containing liquid crystal monomers in the organ, obtain the peak area of the corresponding quantitative ion, and then use the matrix standard curve to quantify the detection results; wherein, the matrix standard curve is drawn. Proceed as follows:

1) Standard sample preparation: Accurately weigh the liquid crystal monomer compound standard substance, and use chromatographic grade n-hexane to prepare a standard stock solution of 1000 μgL ^-1 for use. A certain amount of standard stock solution was pipetted, and the standard quantitative curve solution of a series of concentrations (5, 50, 200, 500 and 1000 μg L ⁻¹ ) was prepared by serial dilution using chromatographic grade n-hexane.

2) draw the standard curve: take the standard curve obtained above, detect under GC-MS, take the concentration as the abscissa and the quantitative ion peak area as the ordinate, and draw the standard curve of the corresponding liquid crystal monomer;

Draw the matrix standard curve: take the blank animal organ without liquid crystal monomer as the sample, and obtain the secondary supernatant according to the pretreatment steps; then use nitrogen to blow the secondary supernatant to dryness, use 1) Reconstitute the standard quantitative curve solution prepared in 2); finally, draw the matrix standard curve according to the method in 2).

3. Beneficial effects

Compared with the prior art, the beneficial effects of the present invention are:

(1) Compared with the traditional detection methods (accelerated solvent extraction, ultrasonic-assisted extraction), the problems of complicated processing, high cost, complicated purification, and difficulty in batch operation, the method for measuring liquid crystal monomers in mammalian organs provided by the present invention The detection method of the compound, through the steps of freeze-drying, then grinding, extracting, purifying, drying, reconstituting, and gas chromatography-tandem mass spectrometry detection on mammalian organs, avoiding the use of complicated equipment such as accelerated solvent extraction apparatus, can realize mammalian organs. The rapid, simple, low-cost, robust and safe detection of liquid crystal monomers in vivo provides a new method for the extraction and analysis of liquid crystal monomers in mammalian organs, and also provides opportunities for future environmental monitoring in mammalian tissues and organs. The extraction and purification procedures of liquid crystal monomer compounds provide a reference;

(2) The detection method for the determination of liquid crystal monomer compounds in mammalian organs provided by the present invention, by performing freeze-drying, then grinding, extraction, purification, drying, and reconstitution on the mammalian organs, the mammalian organs are subjected to The extraction solution of liquid crystal monomer compounds in mammalian organs is obtained by pretreatment. The liquid crystal monomer compounds have high extraction rate, low pollution and high precision, realizes rapid batch pretreatment, effectively reduces matrix interference, and uses matrix Quantitative analysis of standard curve to avoid the inaccuracy of sample determination under the influence of matrix effect, and the target analyte can be obtained with high recovery rate;

Then, compared with the gas chromatography-triple quadrupole mass spectrometry and other instruments currently used in the environmental detection of liquid crystal monomers, the present invention adopts the single quadrupole GC-MS as the detection instrument, and under the condition of ensuring the precision, The use conditions of the instrument are optimized to the greatest extent, and a reliable detection condition with low requirements for instruments and equipment, low cost, simple operation and wide applicability is provided;

Based on this, the instrumental limit of detection (LOD) of the quantitative mammalian organ LCMs under different matrices is as low as 0.123 μg L ^-1 -1.379 μg L ^-1 , and the lower limit of quantification (LOQ) is 1.00×10 ^-3ng —9.83× ^10-2ng . The linear correlation coefficients are all R ² >0.99, and the average recoveries measured under three added concentrations are between 74.4% and 117.0%. After purification by the method established in the present invention, the matrix effect is small.

(3) The detection method for the determination of liquid crystal monomer compounds in mammalian organs provided by the present invention, first freeze-drying, and then perform subsequent operations, and then blow-drying with nitrogen gas can effectively freeze in advance to remove moisture in the sample, which is beneficial to animal samples Grinding treatment and the removal of water at the same time reduce the water removal process in the subsequent steps, reduce the experimental operation steps, improve the batch processing efficiency of samples, reduce the use of solvents, and avoid liquid-liquid phase separation.

Compared with the pre-treatment method of "sample crushing, acetonitrile extraction and separation, MgSO ₄ and other salts to remove water, drying, and redissolving", in the present invention 1) first freeze-drying can remove the moisture in the sample, so that the mammalian sample can be dehydrated. Grinding is simple, and grinding is fragile; 2) Only one solvent is used for extraction, which avoids steps such as adding salt for phase separation of acetonitrile and aqueous solution, and also removes the step of intermediate water removal, which reduces the complexity of the operation and reduces the detection results. 3) The volume of solvent used is small, and the chromatographic-grade n-hexane is reconstituted after drying with nitrogen. The operation is simple and fast. Compared with the traditional large-volume solvent, repeated ultrasonic extraction can save solvent and shorten the extraction time. Blow-drying time improves the efficiency of batch processing of samples.

Description of drawings

Fig. 1 is the structural information of LCMs of the present invention;

Fig. 2 is the analysis schematic diagram of the rapid detection method of LCMs content in the mouse organ established by the embodiment of the present invention;

Fig. 3 is the standard curve of the quick detection method of LCMs content in the mouse organ established in the embodiment of the present invention;

FIG. 4 shows the adsorption of target analytes by different purifiers when purifiers are selected in the establishment process of the embodiment of the present invention.

Detailed ways

The present invention is further described below in conjunction with specific embodiments, but the embodiments do not limit the present invention in any form. Unless otherwise specified, the reagents, methods and equipment used in the present invention are conventional reagents, methods and equipment in the technical field;

The essential features and remarkable effects of the present invention can be embodied in the following embodiments, and the described embodiments are part of the embodiments of the present invention, not all of the embodiments; therefore, they do not limit the present invention in any way. Those skilled in the art can make some non-essential improvements and adjustments according to the content of the present invention, which all belong to the protection scope of the present invention.

Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs; terms used herein and/or terms that include one or more of the associated listed items Any and all combinations.

In this paper, the described "not lower than" a certain value or "not higher than" a certain value, its range should be understood as including the value, for example, "the time is not less than 5min", it should be understood as "the time can be 5min, or longer than 5min”.

In this paper, the steps of drawing the standard curve are as follows:

1) Standard sample preparation: Accurately weigh the liquid crystal monomer compound standard substance, and use chromatographic grade n-hexane to prepare a standard stock solution of 1000 μgL-1 for use. Pipette a certain amount of standard stock solution and dilute it step by step to prepare standard quantitative curve solutions of a series of concentrations (5, 50, 200, 500 and 1000 μg L-1) using chromatographic grade n-hexane.

2) draw the standard curve: take the standard curve obtained above, detect under GC-MS, take the concentration as the abscissa and the quantitative ion peak area as the ordinate, and draw the standard curve of the corresponding liquid crystal monomer;

In subsequent specific embodiments, the standard song used is shown in FIG. 3 .

The present invention will be further described below with reference to specific embodiments.

Example 1

Taking mice as a representative, the detection of LCMs content in mammalian organs was carried out. The contents of four liquid crystal monomer compounds in the heart, liver, lung, brain and kidney of the mice were detected; the liquid crystal monomer compounds were specifically 3dFB, 2OdF3B, 2teFT and 6OCB as shown in FIG. 1 .

As shown in Figure 2, the detection steps in this embodiment are specifically:

1. Pretreatment of mouse organ samples: The mouse organ samples were freeze-dried in a freeze dryer, ground and crushed; 0.1 g of crushed mouse organ samples were weighed into a centrifuge tube, and 2 mL of 0.1% (volume fraction) formic acid acetonitrile was added. The solution was vortexed evenly, then vortexed at 2000rpm for 10min; then sonicated for 15min, vortexed again for 10min, and then centrifuged at 4000rpm for 5-15min to obtain a supernatant;

The primary supernatant was added to a centrifuge tube containing 80 mg C18 and 100 mg PSA, shaken by hand, vortexed for 30 s, and then centrifuged at 4000 rpm for 10 min to obtain a secondary supernatant;

Accurately pipette 1 mL of the secondary supernatant into a centrifuge tube and blow it to near dryness under nitrogen;

2. Draw the matrix standard curve

Then, reconstitute the standard curve according to the above-mentioned "steps for drawing a standard curve" 1), and draw a matrix standard curve according to the above-mentioned "steps for drawing a standard curve" 2).

3. Determination of liquid crystal monomer content in mouse organs

Use gas chromatography-tandem mass spectrometry (GC-MS) to detect the sample obtained in step (3) to obtain the peak area of the corresponding quantitative ion; at the same time, detect the matrix standard curve in step (4), and use the matrix standard curve to quantitatively test Sample.

A certain volume of chromatographic grade n-hexane was used to redissolve to obtain a sample of liquid crystal monomer in the mouse organ after pretreatment.

Among them, the GC-MS detection conditions are as follows:

Gas chromatography conditions: Column: HP-5MS capillary column (30m×0.25mm×0.25μm); carrier gas: high-purity helium, purity ≥99.999%, flow rate 1.0mL min-1; injection method: splitless injection Injection volume: 1 μL; Injector temperature: 290°C; Temperature program: 100°C at 25°C/min to 250°C, hold for 3min, then 10°C/min to 270°C, hold for 1min, then Rise to 280°C at 10°C/min and hold for 4 min.

Mass spectrometry conditions: ion source temperature: 280°C; transfer line temperature: 290°C; solvent delay: 5 min; acquisition mode: SIM scan. The detection parameters of the 4 LCMs used in this example are as follows in Table 2:

Table 2 Detection parameters of the four LCMs used in this study

Table 3 shows the results of GC-MS detection of the mouse organ samples treated by the pretreatment technology in this example. The instrumental limit of detection (LOD) of LCMs under different matrices in the established quantitative mouse organs was 0.123μg L ^-1 -1.379μg L ^-1 , and the lowest limit of quantification (LOQ) was 1.00×10 ^-3 ng - 9.83 × ^10-2ng . The linear correlation coefficients were all R ² >0.99. The average recovery rate measured under the three added concentrations is between 74.4% and 117.0%; after purification by the method established in the present invention, the matrix effect is small.

Table 3 GC-MS detection results

Example 2

This embodiment is basically the same as Embodiment 1, and the difference is only that the impurity removers are different. As shown in Table 4 below, three groups of experiments are set up in this embodiment:

Table 4 Impurity remover groups

As shown in Figure 4, the present invention finds that 80mg C18 and 100mg will not adsorb the target analyte under the condition that the purification capacity is satisfied;

While 50 mg of GCB will adsorb the target analyte, and the amount of GCB is further reduced to 30 mg, at 10 mg, GCB will still strongly adsorb the target analyte.

Considering the functions of the three adsorbents, GCB is mainly used to adsorb pigments, etc., while the pigment content of biological samples is low, so PSA and C18 are finally selected as purification adsorbents.

The invention only uses C18 and PSA to remove the influence of impurities such as fats and proteins in mouse organs, reduces the influence of the matrix in the subsequent sample measurement process, saves the use cost of GCB, and optimizes the purified materials. Simultaneous use of adsorbents reduces costs by at least 30%.

Comparative Example 1

This comparative example is basically the same as Example 1, the difference is only that the impurities removal agent is different, and the pretreatment steps of the mouse organs are different, and the specific steps are as follows:

S1. Pulverize and grind the organ;

S2. Weigh 0.1 g of crushed mouse organ sample into a centrifuge tube, add 2 mL of 0.1% (volume fraction) formic acid in acetonitrile and vortex evenly, then vortex for 10 min at 2000 rpm; then ultrasonicate for 15 min, and then vortex again 10min, centrifuged at 4000rpm;

S3. Add salts such as _MgSO to remove water;

S4. Take the supernatant and add it to a centrifuge tube containing 80mg C18 and 100mg PSA, shake by hand for 2s, vortex for 30s, and then centrifuge for 10min; accurately pipette 1mL of the supernatant into the centrifuge tube and blow it to near dryness under nitrogen. A certain volume of chromatographic grade n-hexane was used to redissolve to obtain a sample of liquid crystal monomer in the mouse organ after pretreatment.

Compared with Example 1, in the present invention, because the samples are freeze-dried before sample extraction, the grinding is easy, and compared with water-containing grinding, it is more sufficient, the container is not easily adhered, and the grinding samples are easy to collect. In the extraction process, because of the lyophilization and water removal in advance, when using acetonitrile formic acid as the solvent for extraction, there is no need to carry out the salt separation step of acetonitrile and the water phase, avoiding the introduction of impurities, and also eliminating the step of removing water, saving extraction. It saves the time of salt and other reagents, especially when a large batch of samples is extracted, it can save at least 30% of the extraction time. With the detection of GC-MS instrument, the present invention can be used more widely.

Example 3

Taking mice as a representative, the detection of LCMs content in mammalian organs was carried out. The contents of four liquid crystal monomer compounds in the heart, liver, lung, brain and kidney of the mice were detected; the liquid crystal monomer compounds were specifically 3dFB, 2OdF3B, 2teFT and 6OCB as shown in FIG. 1 .

As shown in Figure 2, the detection steps in this embodiment are specifically:

1. Pretreatment of mouse organ samples: The mouse organ samples were freeze-dried in a freeze dryer, ground and crushed; 0.1 g of crushed mouse organ samples were weighed into a centrifuge tube, and 2 mL of 0.2% (volume fraction) formic acid acetonitrile was added The solution was vortexed evenly, then vortexed at 3000 rpm for 5 min; then sonicated for 30 min, vortexed for 5 min, and centrifuged at 3000 rpm for 15 min to obtain a supernatant;

Take the primary supernatant and add it to a centrifuge tube containing 70 mg C18 and 110 mg PSA, shake it by hand, vortex for 10 s, and then centrifuge for 5 min at 5000 rpm to obtain a secondary supernatant;

Accurately pipette 1 mL of the secondary supernatant into a centrifuge tube and blow it to near dryness under nitrogen;

2. Draw the matrix standard curve

Then, reconstitute the standard curve according to the above-mentioned "steps for drawing a standard curve" 1), and draw a matrix standard curve according to the above-mentioned "steps for drawing a standard curve" 2).

3. Determination of liquid crystal monomer content in mouse organs

Use gas chromatography-tandem mass spectrometry (GC-MS) to detect the sample obtained in step (3) to obtain the peak area of the corresponding quantitative ion; at the same time, detect the matrix standard curve in step (4), and use the matrix standard curve to quantitatively test Sample.

A certain volume of chromatographic grade n-hexane was used to redissolve to obtain a sample of liquid crystal monomer in the mouse organ after pretreatment.

Among them, the GC-MS detection conditions are as follows:

Gas chromatography conditions: Column: HP-5MS capillary column (30m×0.25mm×0.25μm); carrier gas: high-purity helium, purity ≥99.999%, flow rate 1.0mL min-1; injection method: splitless injection Injection volume: 1 μL; Injector temperature: 290°C; Temperature program: 100°C at 25°C/min to 250°C, hold for 3min, then 10°C/min to 270°C, hold for 1min, then Rise to 280°C at 10°C/min and hold for 4 min.

Mass spectrometry conditions: ion source temperature: 280°C; transfer line temperature: 290°C; solvent delay: 5 min; acquisition mode: SIM scan. The detection parameters of the 4 kinds of LCMs used in this example are as follows in Table 5:

Table 5 Detection parameters of the four LCMs used in this study

In this example, the mouse organ samples treated by the pretreatment technology were detected by GC-MS. The limit of detection (LOD) of LCMs in the established quantitative mouse organs under different matrices was 0.123 μg L ^-1 -1.379μg L ^-1 , the lower limit of quantification (LOQ) was 1.00×10 ^-3 ng—9.83×10 ^-2 ng. The linear correlation coefficients were all R ² >0.99. The average recovery rate measured under the three added concentrations is between 74.4% and 117.0%; after purification by the method established in the present invention, the matrix effect is small.

Example 4

Taking mice as a representative, the detection of LCMs content in mammalian organs was carried out. The contents of four liquid crystal monomer compounds in the heart, liver, lung, brain and kidney of the mice were detected; the liquid crystal monomer compounds were specifically 3dFB, 2OdF3B, 2teFT and 6OCB as shown in FIG. 1 .

As shown in Figure 2, the detection steps in this embodiment are specifically:

1. Pretreatment of mouse organ samples: The mouse organ samples were freeze-dried in a freeze dryer, ground and crushed; 0.1 g of crushed mouse organ samples were weighed into a centrifuge tube, 2 mL of acetonitrile solution was added, vortexed evenly, and then placed in a centrifuge tube. Vortex for 10 min at 3000 rpm; then ultrasonicate for 15 min, vortex for 10 min, and centrifuge at 5000 rpm for 10 min to obtain a supernatant;

Take the primary supernatant and add it to a centrifuge tube containing 100 mg of C18 and 90 mg of PSA, shake it by hand, vortex for 60 s, and then centrifuge for 15 min at 4000 rpm to obtain a secondary supernatant;

Accurately pipette 1 mL of the secondary supernatant into a centrifuge tube and blow it to near dryness under nitrogen;

2. Draw the matrix standard curve

Then, reconstitute the standard curve according to the above-mentioned "steps for drawing the standard curve" 1), and draw the matrix standard curve according to the above-mentioned "steps for drawing the standard curve" 2).

3. Determination of liquid crystal monomer content in mouse organs

Use gas chromatography-tandem mass spectrometry (GC-MS) to detect the sample obtained in step (3) to obtain the peak area of the corresponding quantitative ion; at the same time, detect the matrix standard curve in step (4), and use the matrix standard curve to quantitatively test Sample.

A certain volume of chromatographic grade n-hexane was used to redissolve to obtain a sample of liquid crystal monomer in the mouse organ after pretreatment.

Among them, the GC-MS detection conditions are as follows:

Gas chromatography conditions: Column: HP-5MS capillary column (30m×0.25mm×0.25μm); carrier gas: high-purity helium, purity ≥99.999%, flow rate 1.0mL min-1; injection method: splitless injection Injection volume: 1 μL; Injector temperature: 290°C; Temperature program: 100°C at 25°C/min to 250°C, hold for 3min, then 10°C/min to 270°C, hold for 1min, then Rise to 280°C at 10°C/min and hold for 4 min.

Mass spectrometry conditions: ion source temperature: 280°C; transfer line temperature: 290°C; solvent delay: 5 min; acquisition mode: SIM scan. The detection parameters of 4 kinds of LCMs used in this embodiment are as follows in Table 6:

Table 6 Detection parameters of the four LCMs used in this study

In this example, the mouse organ samples treated by the pretreatment technology were detected by GC-MS. The limit of detection (LOD) of LCMs in the established quantitative mouse organs under different matrices was 0.123 μg L ^-1 -1.379μg L ^-1 , the lower limit of quantification (LOQ) was 1.00×10 ^-3 ng—9.83×10 ^-2 ng. The linear correlation coefficients were all R ² >0.99. The average recovery rate measured under the three added concentrations is between 74.4% and 117.0%; after purification by the method established in the present invention, the matrix effect is small.

Claims (10)

1. a detection method for measuring liquid crystal monomer compounds in mammalian organs, is characterized in that: comprise the following steps: Step 1: pre-processing mammalian organs, and extracting samples containing liquid crystal monomers in the organs; Step 2: use GC-MS to detect the obtained sample sample to obtain the content of liquid crystal monomer; Wherein, the preprocessing includes the following operations: S1. freeze-drying the organ; S2. Grinding after freeze-drying; S3. Extracting the ground organ powder with an acetonitrile solution containing formic acid; then taking the supernatant for drying and redissolving to obtain the sample containing the liquid crystal monomer. 2. The detection method for determining liquid crystal monomer compounds in mammalian organs according to claim 1, wherein the supernatant comprises a primary supernatant and a secondary supernatant; The liquid obtained from the extraction treatment in S3 is subjected to vortexing, ultrasonic/oscillation, vortexing, and centrifugation to obtain the primary supernatant; the primary supernatant is vortexed and centrifuged to obtain the secondary supernatant; or The liquid obtained from the extraction treatment in S3 is subjected to vortexing, ultrasonic/oscillation, vortexing, and centrifugation to obtain the primary supernatant; contacting the primary supernatant with octadecylsilane-bonded silica gel and/or ethylenediamine-N-propylsilane and/or graphene; The contacted primary supernatant is vortexed and centrifuged to obtain a secondary supernatant. 3. The detection method for the determination of liquid crystal monomer compounds in mammalian organs according to claim 2, wherein in the process of obtaining the first supernatant, the first vortexing time is 5-15 min, and the ultrasonic / The shaking time is 10-30 min, the second vortexing time is 5-10 min; the centrifugation time is 5-15 min, and the centrifugal speed is 3000-5000 rpm. 4 . The method for detecting liquid crystal monomer compounds in mammalian organs according to claim 2 , wherein in the process of obtaining the secondary supernatant, the vortexing time is 10-60 s, and the centrifuging time is 5 s. 5 . ~15min, centrifugal speed is 3000 ~ 5000rpm. 5 . The detection method for determining liquid crystal monomer compounds in mammalian organs according to claim 2 , wherein the usage amount of the octadecylsilane-bonded silica gel C18 needs to be 70-100 mg/0.1 g organ. 6 . powder; The usage amount of the ethylenediamine-N-propylsilane needs to be 90-110 mg/0.1 g organ powder. 6 . The detection method for determining liquid crystal monomer compounds in mammalian organs according to claim 2 , wherein: the secondary supernatant is concentrated, dried, and reconstituted to obtain the liquid crystal monomer-containing sample sample. 7 . ; The drying method is slow-flow air blow drying. The solvent used for reconstitution was chromatographic grade n-hexane. 7 . The method of claim 2 , wherein the formic acid-containing acetonitrile solution is a 0-0.2% formic acid (v/v) acetonitrile solution. 8 . 8. The detection method for measuring liquid crystal monomer compounds in mammalian organs according to any one of claims 1-7, wherein the GC-MS detection conditions are as follows: Gas chromatography conditions: Column: HP-5MS capillary column (30m×0.25mm×0.25μm); carrier gas: high-purity helium, purity ≥99.999%, flow rate 1.0mL min-1; injection method: splitless injection Injection volume: 1 μL; Injector temperature: 290°C; Temperature program: 100°C at 25°C/min to 250°C, hold for 3min, then 10°C/min to 270°C, hold for 1min, then Rise to 280°C at 10°C/min and hold for 4 min. Mass spectrometry conditions: ion source temperature: 280°C; transfer line temperature: 290°C; solvent delay: 5 min; acquisition mode: SIM scan. 9 . The detection method for determining liquid crystal monomer compounds in mammalian organs according to claim 8 , wherein the liquid crystal monomer compounds comprise propyl-3,4-difluorobiphenyl, 4-ethyl Oxy-2,3-difluoro-4'-propyl-1,1'-biphenyl, ethylphenyl-2',3,4,5-tetrafluorobiphenyl and hexyloxybiphenylnitrile. The GC-MS detection parameters of the four LCMs used are shown in the table below:

10. The detection method for determining liquid crystal monomer compounds in mammalian organs according to any one of claims 1-7, characterized in that: using GC-MS to detect and extract a sample sample containing liquid crystal monomers in the organ to obtain The peak area of the corresponding quantitative ion is then used to quantify the detection result using the matrix standard curve; wherein, the drawing steps of the matrix standard curve are as follows: 1) Standard sample preparation: Accurately weigh the liquid crystal monomer compound standard substance, and use chromatographic grade n-hexane to prepare a standard stock solution with a certain concentration for future use; Pipette a certain amount of standard stock solution, dilute step by step and use chromatographic grade n-hexane to prepare a standard quantitative curve solution of a series of concentrations; 2) draw the standard curve: take the standard curve obtained above, detect under GC-MS, take the concentration as the abscissa and the quantitative ion peak area as the ordinate, and draw the standard curve of the corresponding liquid crystal monomer; 3) Draw the matrix standard curve: take the blank animal organ without liquid crystal monomer contamination as the sample, and obtain the secondary supernatant according to the pretreatment steps; Then, the secondary supernatant is blown with nitrogen to dryness, and the standard quantitative curve solution prepared in 1) is used to redissolve; Finally, draw the matrix standard curve according to the method in 2).

Images